LIMINATUS PHARMA, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LIMINATUS PHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $3.45M.
- LIMINATUS PHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $15.00M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $3.45M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $15.00M S-1 · filed 2026-06-24 | |
| 2025-06-30 | $15.00M 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |